Connect
Meet the Team
Ramakrishna Dasoju
Over two decades in the CRO/CDMO arena, I shaped and executed programs spanning discovery, preclinical, CMC development, GMP manufacturing, and early-phase clinical research across US, European, and Asia-Pacific biotech and pharma companies. I encompassed building business development teams, managing integrated drug development value chains, and bridging operational and regulatory divides between Western sponsors and Indian service providers. During this tenure, I witnessed too many programs derailed by misalignment, weak partner governance or documentation gaps; therefore, I founded Aventiq Bio with one clear mission: to deliver outsourcing to India with 100% conviction, zero surprises, and uncompromised regulatory/quality standards. I now lead Aventiq Bio in raising the benchmark — by choosing the right partner, managing the program end-to-end, and ensuring your IND/CMC success from day one. I guarantee that when you engage Aventiq Bio, you are backed by someone who's walked both sides of the table — as a sponsor and a service provider — and demands the same discipline you expect in the US/Europe.
Dr. Edwin Gershom
Dr. Edwin Gershom is a PhD-trained scientist (Pathology & Laboratory Medicine) with over a decade of experience in preclinical drug development and translational research across academia, biotech, and CRO environments. He brings a strong track record of advancing therapeutic programs from early discovery through IND-enabling studies and into clinical development.
Dr. Gershom specializes in designing and advising on preclinical strategies spanning efficacy, PK/PD, safety, and IND-enabling toxicology. He has supported biotech, pharmaceutical, and academic partners across oncology, immunology, and infectious diseases, ensuring programs are scientifically rigorous, clinically relevant, and positioned for successful translation.
Prior to Aventiq Bio, Dr. Gershom played key roles at leading CRO and innovation organizations, where he guided end-to-end preclinical programs, aligned study designs with regulatory expectations, and integrated biomarker and translational strategies to de-risk clinical development.
At Aventiq Bio, Dr. Gershom partners with clients to navigate the complexity of the drug development landscape, bridging science, strategy, and execution to accelerate the path from discovery to clinic—and ultimately to improved patient outcomes.
K. Priyanka
Priyanka's role at Aventiq Bio is to bridge the operational divide through radical transparency and relentless follow-through. Armed with an advanced degree in Biotechnology and CRO work experience, she leverages her background in molecular biology and regulatory-aligned documentation to de-risk our partners' programs. She won't just track timelines; she will manage the entire development lifecycle to eliminate the misalignment and governance gaps that too often stall global programs. By ensuring 100% conviction in our delivery and zero technical gaps in our reporting, she provides the operational backbone that turns our corporate strategy into IND/CMC success.
Ganty Phanisree
With a Master's in Pharmaceutical Technology, Phanisree brings a vital dual perspective to Aventiq Bio: a deep-rooted technical understanding of drug development and the strategic acumen required to drive business growth. She leverages this foundation to navigate the complex CRO and CDMO landscape, building high-value partnerships across the biopharmaceutical and research sectors. By accurately assessing partner capabilities and identifying ideal avenues for collaboration, Phanisree helps clients secure the right development partners to accelerate commercialization. She is dedicated to ensuring that every relationship she builds supports Aventiq Bio's mission of reducing technical risk, backed by a strategy that is as scientifically rigorous as it is commercially sound.